Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.45 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 4/20 | 0.37 |
| ▸ | ACACA | Q13085 | 4/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31396268 | 0.83 | GPR119 (0.43) | PDE10ACKS1BSKP1SKP2NAMPT | |
| SCHEMBL31400884 | 0.82 | PDE10A (0.42) | PDE10ANAMPT | |
| SCHEMBL31400908 | 0.82 | PDE10A (0.42) | PDE10ANAMPT | |
| SCHEMBL31400522 | 0.82 | PDE10A (0.42) | PDE10ANAMPT | |
| SCHEMBL23706015 | 0.79 | L3MBTL1 (0.41) | PDE10ACKS1BSKP1SKP2MCHR1 | |
| SCHEMBL31401410 | 0.79 | PDE10A (0.55) | PDE10AHSD11B1NAMPTMAP4K4AOC3 | |
| SCHEMBL31400464 | 0.78 | PDE10A (0.38) | PDE10AMAP4K4 | |
| SCHEMBL31400594 | 0.78 | PDE10A (0.38) | PDE10AMAP4K4 | |
| SCHEMBL31400488 | 0.78 | PDE10A (0.38) | PDE10AMAP4K4 | |
| SCHEMBL31400796 | 0.77 | KCNJ1 (0.40) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025008058-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |